share_log

Wedbush Downgrades Fusion Pharmaceuticals to Neutral, Announces $24 Price Target

Benzinga ·  Mar 19 10:20

Wedbush analyst David Nierengarten downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Outperform to Neutral and announces $24 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment